- Home
- HMY vs VTRS Comparison
HMY vs VTRS Comparison
Compare HMY & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMY
- VTRS
- Stock Information
- Founded
- HMY 1950
- VTRS 1961
- Country
- HMY South Africa
- VTRS United States
- Employees
- HMY N/A
- VTRS N/A
- Industry
- HMY Precious Metals
- VTRS Medicinal Chemicals and Botanical Products
- Sector
- HMY Basic Materials
- VTRS Health Care
- Exchange
- HMY Nasdaq
- VTRS Nasdaq
- Market Cap
- HMY 12.4B
- VTRS 12.2B
- IPO Year
- HMY N/A
- VTRS N/A
- Fundamental
- Price
- HMY $18.88
- VTRS $11.01
- Analyst Decision
- HMY Buy
- VTRS Hold
- Analyst Count
- HMY 3
- VTRS 6
- Target Price
- HMY $12.20
- VTRS $11.17
- AVG Volume (30 Days)
- HMY 5.0M
- VTRS 9.0M
- Earning Date
- HMY 01-01-0001
- VTRS 11-06-2025
- Dividend Yield
- HMY 0.93%
- VTRS 4.29%
- EPS Growth
- HMY 67.74
- VTRS N/A
- EPS
- HMY 1.29
- VTRS N/A
- Revenue
- HMY $4,161,584,110.00
- VTRS $14,124,400,000.00
- Revenue This Year
- HMY $35.41
- VTRS N/A
- Revenue Next Year
- HMY $9.60
- VTRS $1.61
- P/E Ratio
- HMY $13.92
- VTRS N/A
- Revenue Growth
- HMY 20.39
- VTRS N/A
- 52 Week Low
- HMY $7.97
- VTRS $6.85
- 52 Week High
- HMY $22.25
- VTRS $13.55
- Technical
- Relative Strength Index (RSI)
- HMY 60.29
- VTRS 64.07
- Support Level
- HMY $15.14
- VTRS $9.92
- Resistance Level
- HMY $16.57
- VTRS $11.28
- Average True Range (ATR)
- HMY 0.61
- VTRS 0.34
- MACD
- HMY 0.12
- VTRS 0.05
- Stochastic Oscillator
- HMY 94.61
- VTRS 80.88
About HMY Harmony Gold Mining Company Limited
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.